On the mBC Phase 1/2 clinical trial in combination trial.
"This trial will be initiated once GMP RC220 is available, and after the completion of toxicology studies, ethics submission, and regulatory approvals. The expected timeframe for trial commencement is Q3 CY 2024."
Another 12 months before recruitment begins...
- Forums
- ASX - By Stock
- Ann: Race Strategic Update August 2023
RAC
race oncology ltd
Add to My Watchlist
3.38%
!
$1.15

On the mBC Phase 1/2 clinical trial in combination trial."This...
-
- There are more pages in this discussion • 173 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.15 |
Change
-0.040(3.38%) |
Mkt cap ! $198.9M |
Open | High | Low | Value | Volume |
$1.22 | $1.22 | $1.13 | $132.0K | 114.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 2390 | $1.14 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.18 | 4805 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2390 | 1.140 |
3 | 5274 | 1.135 |
4 | 7220 | 1.130 |
1 | 2008 | 1.125 |
5 | 14965 | 1.120 |
Price($) | Vol. | No. |
---|---|---|
1.180 | 4805 | 1 |
1.205 | 2500 | 1 |
1.220 | 21445 | 4 |
1.230 | 7500 | 2 |
1.245 | 2000 | 1 |
Last trade - 15.57pm 04/07/2025 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online